This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of astragaloside supplementation on joint discomfort in healthy adults. The primary goal is to determine if daily intake of astragaloside can improve knee joint function and reduce discomfort over a 12-week period. Participants will be randomly assigned to receive either an astragaloside capsule or a placebo capsule once daily. Aim to see if those taking astragaloside experience better mobility and fewer joint-related symptoms compared to those in the placebo group.
The purpose of this randomized, double-blind clinical trial is to investigate the efficacy of astragaloside supplementation in enhancing joint health and physical function among healthy individuals aged 20 to 70 years. Study Design and Procedures: Participants will be randomized into two groups: the intervention group (astragaloside) and the control group (placebo). Each participant will be instructed to consume one capsule daily after a meal for 12 weeks. The study aims to address the following objectives: Physical Function Assessment: To evaluate changes in knee joint mobility and strength using the Single-Leg Step-Down (SLSD) test and Range of Motion (ROM) measurements. Subjective Symptoms and Quality of Life: To assess improvements in knee-related symptoms through the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire. Biological Markers: To analyze blood biomarkers related to joint health and systemic response. Comparative analysis between the astragaloside and placebo groups will be conducted to determine the statistical significance of the supplement's impact on joint function and discomfort.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Enrollment
50
Participants in the Astragaloside Group will receive one astragaloside capsule orally once daily after meals for 12 weeks. The capsule contains the active compound astragaloside, a component of the traditional herb Astragalus. Participants will be asked to continue their usual diet and physical activity levels during the study.
Participants in the Placebo Group will receive one maltodextrin capsule orally once daily after meals for 12 weeks. The capsule is identical in appearance to the astragaloside capsule but contains no active astragaloside. Participants will be asked to continue their usual diet and physical activity levels during the study.
Chung Shan Medical University
Taichung, Taiwan
Change from baseline in knee joint stability via SLSD test at 12 weeks.
The SLSD test evaluates functional knee stability and lower extremity muscle strength. The examiner records the number of successful repetitions or a quality score based on trunk and limb alignment. Higher scores (or higher number of repetitions) indicate better functional stability and joint control.
Time frame: From baseline to Week 12
Change from baseline in knee Range of Motion (ROM) at 12 weeks.
Knee ROM measures the degree of flexion and extension using a universal goniometer. The measurement is recorded in degrees. An increase in the range of degrees indicates improved joint mobility.
Time frame: From baseline to Week 12
Change from baseline in KOOS score at 12 weeks.
The KOOS questionnaire consists of 5 subscales: Pain, Symptoms, Activities of Daily Living, Sport and Recreation Function, and Knee-related Quality of Life (QOL). Standardized answer options are given (5-point Likert scale). Each subscale score is calculated as a percentage from 0 to 100. A score of 100 represents no knee problems and 0 represents extreme knee problems; therefore, a higher score indicates better outcomes.
Time frame: From baseline to Week 12
Change from baseline in serum inflammatory cytokine levels at 12 weeks.
This measure evaluates the systemic inflammatory response by analyzing the concentrations of Pro-inflammatory cytokines, including Interleukin-6 (IL-6), Interleukin-8 (IL-8), Interleukin-1 beta (IL-1b), and Macrophage Inflammatory Protein-1 alpha (MIP1a). Blood samples will be analyzed using Enzyme-Linked Immunosorbent Assay (ELISA). A decrease in these biomarker concentrations (measured in pg/mL) indicates a reduction in systemic or joint-related inflammation.
Time frame: From baseline to Week 12
Change from baseline in cartilage turnover biomarkers at 12 weeks.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
This measure assesses the balance between cartilage degradation and synthesis. Degradation Markers: C-terminal telopeptide of type II collagen (CTX-II), Cartilage Oligomeric Matrix Protein (COMP), and Matrix Metalloproteinase-13 (MMP-13). Synthesis Markers: Type II collagen markers (COL2a, PIIPC, and PIINP). Samples will be analyzed via ELISA. Lower levels of degradation markers and stable or higher levels of synthesis markers indicate improved cartilage health and reduced joint tissue breakdown.
Time frame: From baseline to Week 12